TrialDiabetes, obesity & metabolism2025

Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.

Domenica M Rubino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.